ClinConnect ClinConnect Logo
Search / Trial NCT06767202

Relationship Between Exposure to Phenols and Pregnancy Outcomes After Embryo Transfer

Launched by KEQIN LIU · Jan 6, 2025

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Embryo Transfer Dietary Polyphenols Bisphenols

ClinConnect Summary

This clinical trial is looking into how exposure to certain chemicals called phenols might affect pregnancy outcomes after women undergo a procedure known as embryo transfer. The study aims to find out if being exposed to these chemicals is linked to any negative effects on pregnancy for women who are receiving help to become pregnant through assisted reproductive technology, like IVF (in vitro fertilization).

To participate in this study, women must be at least 20 years old, be Chinese citizens, and be receiving treatment at the research center. They should also have complete medical and reproductive information available. However, women who have received donated eggs or sperm, have had their treatment canceled, or have serious health issues that could complicate pregnancy cannot take part. If you join the study, you can expect to share your experiences and information to help researchers understand the potential impact of phenol exposure on pregnancy success.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. Chinese citizens over the age of 20;
  • 2. IVF/ICSI assisted reproductive treatment in our center;
  • 3. Complete clinical data, reproductive outcomes and questionnaire data of both sexes;
  • 4. Knowing about this research and voluntarily accepting this research;
  • Exclusion Criteria:
  • 1. The patient receives sperm or egg donation treatment;
  • 2. The patient gave up the egg collection operation due to various reasons, and the cycle was canceled;
  • 3. The patient abandons treatment before achieving clinical pregnancy, but the fertile frozen embryo is not transferred;
  • 4. There are contraindications to pregnancy, such as serious liver and kidney diseases, malignant tumors, serious mental diseases, uncorrected coagulation function abnormalities or endocrine indicators abnormalities;
  • 5. Incomplete or missing clinical data or follow-up data;

About Keqin Liu

Keqin Liu is a dedicated clinical trial sponsor focused on advancing medical research and therapeutic development. With a commitment to ethical practices and rigorous scientific standards, Liu leads initiatives that explore innovative treatment options across various therapeutic areas. Leveraging extensive expertise in clinical methodologies and regulatory compliance, the organization aims to foster collaborations with healthcare professionals, researchers, and institutions to accelerate the translation of clinical findings into meaningful healthcare solutions. Through a patient-centered approach, Keqin Liu is dedicated to improving health outcomes and contributing to the advancement of medical science.

Locations

Wuhan, Hubei, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported